125 related articles for article (PubMed ID: 27142945)
1. Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.
Mpeta B; Kampira E; Castel S; Mpye KL; Soko ND; Wiesner L; Smith P; Skelton M; Lacerda M; Dandara C
Pharmacogenomics; 2016 May; 17(7):679-90. PubMed ID: 27142945
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
3. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
4. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
BMC Med Genet; 2014 Jul; 15():76. PubMed ID: 24986243
[TBL] [Abstract][Full Text] [Related]
5. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
[TBL] [Abstract][Full Text] [Related]
6. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.
Elens L; Yombi JC; Lison D; Wallemacq P; Vandercam B; Haufroid V
Pharmacogenomics; 2009 Oct; 10(10):1589-97. PubMed ID: 19842932
[TBL] [Abstract][Full Text] [Related]
7. CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.
Olagunju A; Schipani A; Siccardi M; Egan D; Khoo S; Back D; Owen A
Pharmacogenet Genomics; 2014 Sep; 24(9):459-63. PubMed ID: 24950369
[TBL] [Abstract][Full Text] [Related]
8. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F
Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515
[TBL] [Abstract][Full Text] [Related]
9. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
Schipani A; Egan D; Dickinson L; Davies G; Boffito M; Youle M; Khoo SH; Back DJ; Owen A
Antivir Ther; 2012; 17(5):861-8. PubMed ID: 22477766
[TBL] [Abstract][Full Text] [Related]
10. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
[TBL] [Abstract][Full Text] [Related]
11. Influence of SLCO1B1 polymorphisms on lopinavir C
Dragović G; Dimitrijević B; Kušić J; Soldatović I; Jevtović D; Olagunju A; Owen A
Br J Clin Pharmacol; 2020 Jul; 86(7):1289-1295. PubMed ID: 32022294
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.
Decloedt EH; McIlleron H; Smith P; Merry C; Orrell C; Maartens G
Antimicrob Agents Chemother; 2011 Jul; 55(7):3195-200. PubMed ID: 21537021
[TBL] [Abstract][Full Text] [Related]
13. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children.
Bellusci CP; Rocco C; Aulicino P; Mecikovsky D; Curras V; Hegoburu S; Bramuglia GF; Bologna R; Sen L; Mangano A
Gene; 2013 Jun; 522(1):96-101. PubMed ID: 23528223
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily.
Tiraboschi JM; Knobel H; Imaz A; Villar J; Ferrer E; Saumoy M; González A; Rozas N; Vila A; Niubó J; Curto J; Podzamczer D
Antivir Ther; 2016; 21(4):359-63. PubMed ID: 26656921
[TBL] [Abstract][Full Text] [Related]
15. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.
López Aspiroz E; Cabrera Figueroa SE; Iglesias Gómez A; Valverde Merino MP; Domínguez-Gil Hurlé A
Clin Drug Investig; 2015 Jan; 35(1):61-6. PubMed ID: 25391550
[TBL] [Abstract][Full Text] [Related]
16. Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Pucci L; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
J Int AIDS Soc; 2014; 17(4 Suppl 3):19589. PubMed ID: 25394094
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.
López Aspiroz E; Cabrera Figueroa SE; Porras Hurtado GL; Cruz Guerrero R; Domínguez-Gil Hurlé A; Carracedo A;
Curr Drug Metab; 2013 Sep; 14(7):729-37. PubMed ID: 24001122
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
Gupta SK; Rosenkranz SL; Cramer YS; Koletar SL; Szczech LA; Amorosa V; Hall SD
AIDS; 2008 Oct; 22(15):1919-27. PubMed ID: 18784455
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
